GNVR
Genvor Incorporated1.7000
+0.0000+0%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
33.36MP/E (TTM)
-Basic EPS (TTM)
-Dividend Yield
0%Recent Filings
10-Q
Q1 FY2026 results
Genvor posted a narrower Q1 FY2026 operating loss of $563K for the quarter ended December 31, 2025, down 89% y/y from $5.0M, while net loss of $576K trailed operating by just 2% due to $15K related-party interest. Compensation plunged 94% y/y after prior stock grants, yet R&D held steady at $57K amid USDA peptide studies. Cash tripled q/q to $104K via $260K share sales, converting out the $20K note; working capital deficit shrank 19% to $1.1M. Stock issuances funded ops. Litigation drags on ex-exec pay disputes.
10-K
FY2025 results
Genvor posted FY2025 ended September 30, 2025 net loss of $5.6M, up 94% y/y from $2.9M, on zero revenue and operating expenses doubling to $6.4M—R&D up 90%, compensation exploding 317% from stock grants. No Q4 breakdowns disclosed. Cash dwindled to $37K amid $556K operating burn, offset by $525K stock sales; working capital deficit eased to $1.3M after note settlements. Licensing-first model eyes revenue end-2025. No annual guidance given. Going concern doubt looms large.
10-Q
Q2 FY2025 results
Genvor posted no revenue for Q2 FY2025 ended March 31, 2025, with operating expenses dropping 63% y/y to $276K, mainly from slashed professional fees and stock-based comp, yielding a narrower operating loss of $276K versus $747K last year. Yet net loss widened to $299K from $772K, driven by $23K interest on notes and related-party accruals, while YTD net loss ballooned to $5.3M on $4.8M CEO stock grants, up 150% y/y, with EPS at ($0.23) matching 22.8M diluted shares. Cash scraped to $641 after $73K related-party advances covered ops burn, against $2.1M liabilities including $897K notes and $697K accrued pay; free cash flow not disclosed in the 10-Q. Formulation advances for antimicrobial peptides progressed, with Bayer's Golden Ticket boosting R&D momentum. Ongoing litigation over unpaid services poses recovery risks.
10-Q
Q3 FY2025 results
Genvor posted a narrower Q3 operating loss of $578K, up slightly 1.0% y/y, while the nine-month tally swelled to $5.85M from $2.62M y/y, driven by a 345% surge in compensation costs from $4.86M in stock awards to the CEO. Research expenses climbed 521% q/q to $272K on peptide formulation advances, including stable liquid prototypes for GV185 and GV197 antifungals showing IC50 efficacy under 4μM against key pathogens like Fusarium. Cash edged to $99K after $430K from stock sales, but operating burn hit $400K ytd; total debt eased to $746K post-$217K note settlement for shares, leaving a $1.6M working capital gap. No revenue yet, but Bayer's Golden Ticket bolsters lab access for commercialization. Ongoing litigation over unpaid services poses execution risks.
8-K
Genvor updates investor deck
Genvor Incorporated posted its updated September 2025 corporate presentation to its investor website on September 4, 2025, under Item 7.01 for Regulation FD compliance. The deck covers company and business details, yet remains summary information meant to complement full SEC filings and public disclosures. No duty to update exists. Information furnished here isn't deemed filed.
AVD
American Vanguard Corporation
4.02+0.00
BIOX
Bioceres Crop Solutions Corp.
1.51-0.04
CTVA
Corteva, Inc.
65.48-0.40
FMC
FMC Corporation
13.16+0.04
LVRO
Lavoro Limited
0.64-0.02
NTR
Nutrien Ltd.
61.85+0.00
NUVI
Emo Capital Corp.
0.00+0.00
SANW
S&W Seed Co.
0.06+0.00
SEED
Origin Agritech Limited
1.37+0.08
UAN
CVR Partners, LP
94.78-0.78